Myriad Genetics, Inc. (MYGN)

Market Cap	391.75M
Revenue (ttm)	831.30M
Net Income (ttm)	-101.40M
Shares Out	92.18M
EPS (ttm)	-1.12
PE Ratio	n/a
Forward PE	154.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,637,798
Open	4.000
Previous Close	3.890
Day's Range	3.830 - 4.260
52-Week Range	3.980 - 29.300
Beta	2.01
Analysts	Hold
Price Target	16.63 (+291.29%)
Earnings Date	May 6, 2025

About MYGN

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and meta...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 5, 1995
• Employees: 2,700
• Stock Exchange: NASDAQ
• Ticker Symbol: MYGN
• Website: https://www.myriad.com

Financial Performance

In 2024, Myriad Genetics's revenue was $837.60 million, an increase of 11.21% compared to the previous year's $753.20 million. Losses were -$127.30 million, -51.65% less than in 2023.

Analyst Forecast

According to 16 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is $16.63, which is an increase of 291.29% from the latest price.

Price Target

$16.63

(291.29% upside)

Analyst Consensus: Hold